TCRX
Tscan Therapeutics Inc
0.34$
-2.6%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +85.5% | -92.2% | -5.3% | +95.7% | -36.6% | +226.5% | +41.7% | -18.4% | +2.2% | -61.7% | +7.0% | – | |
| – | -0.5% | -2.0% | -11.0% | -8.0% | -30.8% | – | – | – | -5.7% | -4.1% | – | – | |
| – | +52.6% | -90.5% | -5.3% | +95.7% | -36.6% | +226.5% | +41.7% | -18.4% | +2.2% | -88.7% | +263.7% | – | |
| – | -1.5% | +10.9% | +8.1% | -2.3% | +11.8% | +1.5% | +9.6% | -2.9% | -36.8% | +9.3% | +6.8% | – | |
| – | +4.5% | +12.0% | +10.0% | -2.4% | -1.5% | +15.9% | +5.5% | -13.7% | -25.6% | +43.4% | -0.9% | – | |
| – | -4.7% | +17.0% | +8.5% | -2.8% | +11.0% | +2.8% | +8.6% | -5.2% | -33.2% | +11.4% | +7.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -13.2% | +12.6% | -0.7% | +0.6% | -18.2% | -13.4% | +1.5% | +1.5% | +0.4% | -1.9% | +1.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.